Tekla Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Tekla Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$7.45M	Buy	+72,425	New	+$7.64M	0.29%	68
2023 Q1	–	Sell	-415,053	Closed	-$47.2M	–	190
2022 Q4	$47.2M	Sell	415,053 -319,300	-43%	-$26.5M	1.78%	19
2022 Q3	$45.4M	Sell	734,353 -141,736	-16%	-$9.9M	1.86%	18
2022 Q2	$69.9M	Sell	876,089 -83,350	-9%	-$7.89M	2.75%	9
2022 Q1	$101M	Buy	959,439 +61,899	+7%	+$6.03M	3.55%	4
2021 Q4	$96.7M	Sell	897,540 -12,800	-1%	-$1.4M	3.11%	6
2021 Q3	$99.7M	Sell	910,340 -26,000	-3%	-$2.7M	3.21%	5
2021 Q2	$87.7M	Buy	936,340 +125,408	+15%	+$11.5M	2.85%	6
2021 Q1	$74.6M	Buy	810,932 +345,916	+74%	+$29.2M	2.57%	8
2020 Q4	$34M	Sell	465,016 -138,668	-23%	-$10.3M	1.2%	21
2020 Q3	$46.9M	Buy	603,684 +193,531	+47%	+$13.3M	1.76%	15
2020 Q2	$22.8M	Buy	410,153 +10,896	+3%	+$466K	0.87%	26
2020 Q1	$11.8M	Buy	399,257 +94,593	+31%	+$3.2M	0.53%	42
2019 Q4	$11M	Buy	304,664 +89,934	+42%	+$2.76M	0.42%	53
2019 Q3	$5.85M	Buy	214,730 +57,257	+36%	+$1.48M	0.26%	73
2019 Q2	$3.79M	Buy	157,473 +138,123	+714%	+$3.5M	0.15%	104
2019 Q1	$511K	Buy	+19,350	New	+$459K	0.02%	180
2018 Q4	–	Sell	-162,900	Closed	-$3.19M	–	217
2018 Q3	$3.19M	Hold	162,900	–	–	0.12%	118
2018 Q2	$2.7M	Hold	162,900	–	–	0.1%	122
2018 Q1	$2.31M	Hold	162,900	–	–	0.09%	128
2017 Q4	$2.38M	Hold	162,900	–	–	0.09%	121
2017 Q3	$2.07M	Hold	162,900	–	–	0.07%	120
2017 Q2	$1.93M	Hold	162,900	–	–	0.07%	113
2017 Q1	$2.41M	Hold	162,900	–	–	0.09%	105
2016 Q4	$2.64M	Sell	162,900 -587,000	-78%	-$10.6M	0.11%	95
2016 Q3	$13.6M	Hold	749,900	–	–	0.52%	44
2016 Q2	$12.4M	Hold	749,900	–	–	0.5%	49
2016 Q1	$12.4M	Hold	749,900	–	–	0.53%	44
2015 Q4	$16.3M	Buy	749,900 +587,000	+360%	+$11.4M	0.59%	35
2015 Q3	$3.23M	Buy	+162,900	New	+$5.15M	0.12%	125

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tekla Capital Management's HZNP Position: Q2 2023 in Review

Tekla Capital Management opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023: 72,425 shares worth $7.45M. The stake represents 0.29% of the portfolio and ranks #68 among its holdings. This is a return to the name: Tekla Capital Management previously reported a position in HZNP as recently as Q4 2022.

Tekla Capital Management first reported a position in HZNP in Q3 2015 and has held it in 30 quarters since. The position peaked at $101M in Q1 2022. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Tekla Capital Management held 72,425 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $7.45M as of Q2 2023.
Horizon Therapeutics Public Limited Company Ordinary Shares was a new Tekla Capital Management position in Q2 2023.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.29% of Tekla Capital Management's portfolio in Q2 2023, its #68 holding.
Tekla Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2015 and has held it in 30 quarters since.
Tekla Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $101M in Q1 2022.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.